Navigation Links
Experimental cancer pharmaceuticals under trial
Date:10/23/2007

A potent and selective inhibitor of the mitotic kinesin CENP-E (GSK923295A) demonstrates a novel mechanism of inhibiting tumor cell proliferation and shows activity against a broad panel of human tumor cell lines in vitro: Abstract A 111.

A first-in-class, targeted investigational therapy specifically designed to inhibit a single protein that functions only during cell division shows potent activity in a broad range of cancer cell lines, say researchers from GlaxoSmithKline. Because the compound is so specifically targeted, it may help reduce some of the more common toxic side effects of chemotherapy, they say.

The experimental drug, GSK923295A, inhibits the mitotic kinesin centromere-associated protein E (CENP-E), which is required during mitosis, the process by which a cell duplicates its genetic information in order to generate two, identical, daughter cells. The resulting mitotic arrest can lead to apoptosis, or cell death. A characteristic of CENP-E inhibition is the presence of misaligned or lagging chromosomes within cells attempting to replicate.

Investigators were able to observe lagging chromosomes in most tumor cells treated with GSK923295A. These effects are rarely observed in untreated cells, said the studys lead investigator, David Sutton, B.Sc., associate director of biology, within the Oncology division of GlaxoSmithKline in Collegeville, Pa. GlaxoSmithKline funded the study.

Although CENP-E is expressed in all dividing cells, GSK923925A is more likely to affect rapidly dividing cancer cells, Sutton says. Furthermore, because of the very low expression of CENP-E in non-dividing cells such as neurons, GSK923295A may not cause the peripheral nerve damage often seen with chemotherapy treatments such as taxanes and vinca alkaloids, which also inhibit mitosis, he says.

Studies conducted in animal models have shown complete tumor regression in some cancer types, says Sutton. In preclinical tests conducted in 214 solid and 85 hematological tumor cell lines, sensitivity to GSK923295A was seen in 16 out of 17 breast tumor cell lines, 20 out of 25 colon cancer lines, 24 out of 26 lung cancer lines, 11 out of 11 ovarian cancer lines, and six out of six prostate cancer lines, he says. Additionally, laboratory analysis suggests that anti-tumor activity might be achieved with minimal suppression of the bone marrow, which could reduce the typical myelosuppression (reduction in production of blood cells) seen with chemotherapy treatment, he says.

It is a big leap from doing laboratory experiments to understanding what will happen in patients, but we think it is very encouraging that this first-in-class drug candidate shows both broad activity and the potential for enhanced tolerability in preclinical studies, Sutton said. GSK923295A, a small molecule drug given intravenously, is now being evaluated in a Phase I clinical trial in patients with advanced solid tumors. It was discovered and optimized by GSK, in partnership with Cytokinetics Inc.


'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — ... Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Pharmaceutical Contract ... ... for the US, Canada , Japan ... Rest of World. Annual estimates and forecasts are provided for the period ... markets. Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: